{"filing":{"accession_number":"0001919246-26-000112","cik":"0001919246","ticker":"PTHS","company_name":"Pelthos Therapeutics Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"pths-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000112/pths-20260813.htm"},"events":[{"id":27486,"run_id":25056,"accession_number":"0001919246-26-000112","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Pelthos Therapeutics disclosed second quarter 2026 financial results via press release, reporting net product revenue of $15.4 million (45% QoQ growth) and a net loss of $(23.4) million, along with operational highlights including Zelsuvmi unit dispensing growth.","company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29051,"accession_number":"0001919246-26-000112","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 2.02 discloses Pelthos Therapeutics' second quarter 2026 financial results via a press release (Exhibit 99.1), showing net product revenue of $15.4 million (45% QoQ growth), net loss of $(23.4) million, and operational highlights including Zelsuvmi unit dispensing growth. The filing explicitly states the press release summarizes \"financial results for the second quarter 2026\" and is furnished as an exhibit, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:16:56.587217+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29052,"accession_number":"0001919246-26-000112","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure incorporates by reference Item 2.02 and Exhibit 99.1, which is a press release announcing Pelthos' second quarter 2026 financial results. The press release discloses net product revenue of $15.4 million (45% QoQ growth), net loss of $(23.4) million, and operational metrics for Zelsuvmi. This is a standard earnings release disclosure, material to investors assessing the company's commercial progress and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:16:56.587217+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29051,"accession_number":"0001919246-26-000112","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 2.02 discloses Pelthos Therapeutics' second quarter 2026 financial results via a press release (Exhibit 99.1), showing net product revenue of $15.4 million (45% QoQ growth), net loss of $(23.4) million, and operational highlights including Zelsuvmi unit dispensing growth. The filing explicitly states the press release summarizes \"financial results for the second quarter 2026\" and is furnished as an exhibit, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:16:56.587217+00:00","company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","filing_date":"2026-08-13"},{"id":29052,"accession_number":"0001919246-26-000112","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure incorporates by reference Item 2.02 and Exhibit 99.1, which is a press release announcing Pelthos' second quarter 2026 financial results. The press release discloses net product revenue of $15.4 million (45% QoQ growth), net loss of $(23.4) million, and operational metrics for Zelsuvmi. This is a standard earnings release disclosure, material to investors assessing the company's commercial progress and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:16:56.587217+00:00","company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","filing_date":"2026-08-13"}]}